Type: Product
Name: Deflux
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Salix Pharmaceuticals to Combine with Cosmo -2-

Salix markets XIFAXAN(R) (rifaximin) tablets 200 mg and 550 mg, MOVIPREP(R) (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution, 100 g/7.5 g/2.691 g/1.015 g/5.9 g/4.7 g), OSMOPREP(R) (sodium ... [Published Scottrade - Jul 08 2014]


...event for Salix and an important milestone in its growth as the leading gastroenterology-focused specialty pharmaceutical company in the US. "The creation of a larger, stronger Salix reinforces our premier position in gastroenterology and creates the opportunity for us to expand our digestive disease expertise into other key specialties" Logan added. Latest News

More Content

All (5) | News (3) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Salix Pharmaceuticals to Combine with Cosmo -2- [Published Scottrade - Jul 08 2014]
Salix Pharmaceuticals completes $2.6bn acquisit... [Published Pharmaceutical Business Review - Jan 03 2014]
Salix announces approval of additional injectio... [Published Pharmaceutical Business Review - Nov 19 2013]
Fact Sheet for Q-Med AB [Published Able2Act - Jul 16 2008]
Fact Sheet for Q-Med [Published Able2Act - Feb 12 2008]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.